Fellowship · Rochester, NY
Sponsored by University of Rochester Medicine
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial.
Nature medicine · 2025 · 143 citations · Emma Ciafaloni
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis.
The New England journal of medicine · 2025 · 51 citations · Emma Ciafaloni
Electrodiagnostic assessment of the autonomic nervous system: A consensus statement endorsed by the American Autonomic Society, American Academy of Neurology, and the International Federation of Clinical Neurophysiology.
Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2021 · 144 citations · Pariwat Thaisetthawatkul
Systematic review of frequency of felt and enacted stigma in epilepsy and determining factors and attitudes toward persons living with epilepsy-Report from the International League Against Epilepsy Task Force on Stigma in Epilepsy.
Epilepsia · 2022 · 87 citations · Gretchen Birbeck
Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
JAMA · 2022 · 116 citations · Emma Ciafaloni
Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study.
Neurology · 2022 · 99 citations ·
The global prevalence of headache disorders of public-health importance: a meta-analysis of population-based individual participant data from 41,614 adults from 17 countries.
The journal of headache and pain · 2025 · 21 citations · Gretchen Birbeck
Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial.
The Lancet. Neurology · 2024 · 34 citations · Johanna Hamel